How recurrent kidney cancer is found — the follow-up scans and checks that pick it up

Most recurrences are picked up on a routine follow-up scan rather than because someone felt unwell. After treatment for kidney cancer you are placed on a surveillance schedule - imaging of the chest and abdomen at set intervals, with blood tests and a clinical review alongside. How closely you are followed is set by the stage and the pathology of the original tumour, along NCCN lines. A smaller number of recurrences are found because a new symptom brought a scan forward - a cough that will not settle, new bone pain, or blood in the urine. Either way, what is found first is a picture on a scan. It becomes a diagnosis only after it has been checked.

Very often there is no sign at all, which is exactly why surveillance imaging exists. When symptoms do appear they usually point to where the cancer has settled rather than to the kidney itself: a cough or breathlessness that does not settle, new and persistent bone pain, an ache in the flank or around the surgical scar, unexplained weight loss, or blood in the urine if a kidney or part of one remains. None of these means recurrence on its own, and all of them are far more often caused by something ordinary. What matters is that a new symptom which persists gets checked promptly rather than left until the next scheduled scan.

Follow-up usually combines a CT of the chest and abdomen with contrast, sometimes an ultrasound of the remaining kidney or the surgical bed, and an MRI where contrast cannot be given or where a finding needs better characterisation. Using the same modality each time is deliberate: the radiologist is looking for change against your previous scans, not simply at today's picture. CT, ultrasound, MRI, biopsy and the blood work around them are delivered in-house at CION by our own team. PET-CT is used selectively in kidney cancer rather than routinely, and where it is needed we coordinate it with specialist imaging and interventional radiology partners, where it may also be billed.

No. Small indeterminate findings are common on surveillance scans and most turn out to be harmless - old scarring, an infection that has healed, a small benign nodule, or changes at the surgical site left by the operation itself. That is why the usual next step is a repeat scan after a short interval rather than immediate treatment: something that stays exactly the same over time is behaving very differently from something that is growing. Being told a finding will be watched is not the team stalling. It is the quickest way to answer the question without putting you through a procedure you may not need.

Not always. Where a new lesion has clearly grown between two scans, sits in a typical location and looks characteristic on imaging in someone with a known kidney cancer history, the imaging and the history may be enough for the team to act on. A biopsy is used when the picture is not clear-cut, when the finding could plausibly be a second and unrelated cancer, or when tissue is needed to guide systemic treatment. Biopsy and the pathology that follows it are done in-house at CION. Every result goes to a tumour board rather than to one doctor, so the decision to call something a recurrence is made jointly.

Longer than most people expect. Surveillance is heaviest in the first years after treatment, when a recurrence is most likely, and is spaced out after that - but kidney cancer is known for occasionally returning many years later, so follow-up is not usually stopped abruptly at a fixed anniversary. How long yours continues depends on the stage and grade of the original tumour and on what the pathology showed, along NCCN lines. If your scans have quietly lapsed, or nobody has told you what the plan actually is, that is worth raising. Our team can review your history and set out a written follow-up schedule.